Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2017 (2017), Article ID 7586174, 13 pages
https://doi.org/10.1155/2017/7586174
Review Article

Cytokines in Endocrine Dysfunction of Plasma Cell Disorders

1CHU de Poitiers, Service d’Endocrinologie, Pole DUNE, Poitiers, France
2Université de Poitiers, UFR Médecine Pharmacie, Poitiers, France
3INSERM, CIC 1402 & U1082, Poitiers, France
4INSERM U954, Nutrition Génétique et Exposition aux Risques Environnementaux, Medical Faculty, University of Lorraine and Regional University Hospital Center of Nancy, Vandœuvre-lès-Nancy, France

Correspondence should be addressed to Eva Feigerlová; gro.liamthgirbluf@avolregief.ave

Received 12 January 2017; Accepted 25 May 2017; Published 27 June 2017

Academic Editor: Rajesh Singh

Copyright © 2017 Eva Feigerlová and Shyue-Fang Battaglia-Hsu. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. V. Rajkumar, M. A. Dimopoulos, A. Palumbo et al., “International myeloma working group updated criteria for the diagnosis of multiple myeloma,” The Lancet Oncology, vol. 15, no. 12, pp. e538–e548, 2014. View at Google Scholar
  2. V. Rajkumar, “Myeloma today: disease definitions and treatment advances,” American Journal of Hematology, vol. 91, no. 9, p. 965, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Arnulf, D. Bengoufa, E. Sarfati et al., “Prevalence of monoclonal gammopathy in patients with primary hyperparathyroidism: a prospective study,” Archives of Internal Medicine, vol. 162, no. 4, pp. 464–467, 2002. View at Google Scholar
  4. J. N. Tan, M. H. Kroll, C. J. O'Hara, P. C. Everett, and E. Erdogan, “Gamma heavy chain disease in a patient with underlying lymphoplasmacytic lymphoma of the thyroid. Report of a case and comparison with other reported cases with thyroid involvement,” Clinica Chimica Acta, vol. 413, no. 19-20, pp. 1696–1699, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Otto, I. Peter, S. Vegh, E. Juhos, and I. Besznyak, “Gamma-chain heavy-chain disease with primary thyroid plasmacytoma,” Archives of pathology & laboratory medicine, vol. 110, no. 10, pp. 893–896, 1986. View at Google Scholar
  6. S. Matsubayashi, H. Tamai, T. Suzuki et al., “Extramedullary plasmacytoma of the thyroid gland producing gamma heavy chain,” Endocrinologia Japonica, vol. 32, no. 3, pp. 427–433, 1985. View at Google Scholar
  7. P. A. Bardwick, N. J. Zvaifler, G. N. Gill, D. Newman, G. D. Greenway, and D. L. Resnick, “Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature,” in Medicine, vol. 59, no. 4, pp. 311–322, Baltimore, 1980. View at Publisher · View at Google Scholar
  8. G. D. Miralles, J. R. O'Fallon, and N. J. Talley, “Plasma-cell dyscrasia with polyneuropathy. The spectrum of POEMS syndrome,” The New England Journal of Medicine, vol. 327, no. 27, pp. 1919–1923, 1992. View at Publisher · View at Google Scholar
  9. T. Nakanishi, I. Sobue, Y. Toyokura et al., “The Crow-Fukase syndrome: a study of 102 cases in Japan,” Neurology, vol. 34, no. 6, pp. 712–720, 1984. View at Publisher · View at Google Scholar
  10. M. J. Soubrier, J. J. Dubost, and B. J. Sauvezie, “POEMS syndrome: a study of 25 cases and a review of the literature. French study group on POEMS syndrome,” The American Journal of Medicine, vol. 97, no. 6, pp. 543–553, 1994. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Dispenzieri, R. A. Kyle, M. Q. Lacy et al., “POEMS syndrome: definitions and long-term outcome,” Blood, vol. 101, no. 7, pp. 2496–2506, 2003. View at Google Scholar
  12. A. Dispenzieri, “POEMS syndrome,” Blood Reviews, vol. 21, no. 6, pp. 285–299, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Gherardi, M. Baudrimont, M. Kujas et al., “Pathological findings in three non-Japanese patients with the POEMS syndrome,” Virchows Archiv. A, Pathological Anatomy and Histopathology, vol. 413, no. 4, pp. 357–365, 1988. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Yang, X. Huang, Q. Cai et al., “Improvement of sexual function in POEMS syndrome after combination therapy of lenalidomide and dexamethasone,” Orphanet Journal of Rare Diseases, vol. 11, no. 1, p. 80, 2016. View at Google Scholar
  15. R. N. Dexter, F. Mullinax, H. L. Estep, and R. C. Williams Jr., “Monoclonal IgG gammopathy and hyperparathyroidism,” Annals of Internal Medicine, vol. 77, no. 5, pp. 759–764, 1972. View at Google Scholar
  16. L. Bieghs, M. Brohus, I. B. Kristensen et al., “Abnormal IGF-binding protein profile in the bone marrow of multiple myeloma patients,” PloS One, vol. 11, no. 4, article e0154256, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. R. K. Gherardi, L. Belec, G. Fromont et al., “Elevated levels of interleukin-1 beta (IL-1 beta) and IL-6 in serum and increased production of IL-1 beta mRNA in lymph nodes of patients with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes (POEMS) syndrome,” Blood, vol. 83, no. 9, pp. 2587–2593, 1994. View at Google Scholar
  18. C. Rose, M. Zandecki, M. C. Copin et al., “POEMS syndrome: report on six patients with unusual clinical signs, elevated levels of cytokines, macrophage involvement and chromosomal aberrations of bone marrow plasma cells,” Leukemia, vol. 11, no. 8, pp. 1318–1323, 1997. View at Publisher · View at Google Scholar
  19. A. D'Souza, S. R. Hayman, F. Buadi et al., “The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome,” Blood, vol. 118, no. 17, pp. 4663–4665, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. O. Watanabe, I. Maruyama, K. Arimura et al., “Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome,” Muscle & Nerve, vol. 21, no. 11, pp. 1390–1397, 1998. View at Publisher · View at Google Scholar
  21. M. Soubrier, J. J. Dubost, A. F. Serre et al., “Growth factors in POEMS syndrome: evidence for a marked increase in circulating vascular endothelial growth factor,” Arthritis and Rheumatism, vol. 40, no. 4, pp. 786-787, 1997. View at Publisher · View at Google Scholar
  22. S. Barille, R. Bataille, and M. Amiot, “The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma,” European Cytokine Network, vol. 11, no. 4, pp. 546–551, 2000. View at Google Scholar
  23. N. Shikama, A. Isono, Y. Otsuka, T. Terano, and A. Hirai, “A case of POEMS syndrome with high concentrations of interleukin-6 in pericardial fluid,” Journal of Internal Medicine, vol. 250, no. 2, pp. 170–173, 2001. View at Google Scholar
  24. S. Hitoshi, K. Suzuki, and M. Sakuta, “Elevated serum interleukin-6 in POEMS syndrome reflects the activity of the disease,” Internal Medicine, vol. 33, no. 10, pp. 583–587, 1994. View at Publisher · View at Google Scholar · View at Scopus
  25. D. Ribatti, B. Nico, and A. Vacca, “Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma,” Oncogene, vol. 25, no. 31, pp. 4257–4266, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. A. C. Sprynski, D. Hose, L. Caillot et al., “The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor,” Blood, vol. 113, no. 19, pp. 4614–4626, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Caers, S. Deleu, Z. Belaid et al., “Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells,” Leukemia, vol. 21, no. 7, pp. 1580–1584, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. C. J. Rosen, C. Ackert-Bicknell, J. P. Rodriguez, and A. M. Pino, “Marrow fat and the bone microenvironment: developmental, functional, and pathological implications,” Critical Reviews in Eukaryotic Gene Expression, vol. 19, no. 2, pp. 109–124, 2009. View at Publisher · View at Google Scholar
  29. C. Falank, H. Fairfield, and M. R. Reagan, “Signaling interplay between bone marrow adipose tissue and multiple myeloma cells,” Front Endocrinol (Lausanne), vol. 7, no. 67, 2016. View at Google Scholar
  30. N. Franchimont, S. Wertz, and M. Malaise, “Interleukin-6: an osteotropic factor influencing bone formation?” Bone, vol. 37, no. 5, pp. 601–606, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. S. R. Bornstein, H. Rutkowski, and I. Vrezas, “Cytokines and steroidogenesis,” Molecular and Cellular Endocrinology, vol. 215, no. 1-2, pp. 135–141, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Y. Hong, J. H. Park, R. S. Ahn et al., “Molecular mechanism of suppression of testicular steroidogenesis by proinflammatory cytokine tumor necrosis factor alpha,” Molecular and Cellular Biology, vol. 24, no. 7, pp. 2593–2604, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. P. Liakos, D. Lenz, R. Bernhardt, J. J. Feige, and G. Defaye, “Transforming growth factor beta1 inhibits aldosterone and cortisol production in the human adrenocortical cell line NCI-H295R through inhibition of CYP11B1 and CYP11B2 expression,” The Journal of Endocrinology, vol. 176, no. 1, pp. 69–82, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. C. P. Castro, D. Giacomini, A. C. Nagashima et al., “Reduced expression of the cytokine transducer gp130 inhibits hormone secretion, cell growth, and tumor development of pituitary lactosomatotrophic GH3 cells,” Endocrinology, vol. 144, no. 2, pp. 693–700, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Arzt, R. Buric, G. Stelzer et al., “Interleukin involvement in anterior pituitary cell growth regulation: effects of IL-2 and IL-6,” Endocrinology, vol. 132, no. 1, pp. 459–467, 1993. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Goto, M. Nishio, K. Kumano, K. Fujimoto, K. Yamaguchi, and T. Koike, “Discrepancy between disease activity and levels of vascular endothelial growth factor in a patient with POEMS syndrome successfully treated with autologous stem-cell transplantation,” Bone Marrow Transplantation, vol. 42, no. 9, pp. 627–629, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. J. M. Loeb, P. H. Hauger, J. D. Carney, and A. D. Cooper, “Refractory ascites due to POEMS syndrome,” Gastroenterology, vol. 96, no. 1, pp. 247–249, 1989. View at Publisher · View at Google Scholar
  38. M. Scarlato, S. C. Previtali, M. Carpo et al., “Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis,” Brain, vol. 128, Part 8, pp. 1911–1920, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. X. Y. Dun, F. Zhou, H. Xi, Z. G. Yuan, and J. Hou, “Thyroid function and its clinical significance in POEMS syndrome,” Leukemia & Lymphoma, vol. 50, no. 12, pp. 2013–2016, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. D. Fee, D. Grzybicki, M. Dobbs, S. Ihyer, J. Clotfelter, and S. Macvilay, “Interleukin 6 promotes vasculogenesis of murine brain microvessel endothelial cells,” Cytokine, vol. 12, no. 6, pp. 655–665, 2000. View at Publisher · View at Google Scholar · View at Scopus
  41. B. Motro, A. Itin, L. Sachs, and E. Keshet, “Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 8, pp. 3092–3096, 1990. View at Google Scholar
  42. W. T. Bellamy, L. Richter, Y. Frutiger, and T. M. Grogan, “Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies,” Cancer Research, vol. 59, no. 3, pp. 728–733, 1999. View at Google Scholar
  43. B. Dankbar, T. Padro, R. Leo et al., “Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma,” Blood, vol. 95, no. 8, pp. 2630–2636, 2000. View at Google Scholar
  44. G. Skiniotis, M. J. Boulanger, K. C. Garcia, and T. Walz, “Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor,” Nature Structural & Molecular Biology, vol. 12, no. 6, pp. 545–551, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. K. Tawara, J. T. Oxford, and C. L. Jorcyk, “Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies,” Cancer Management and Research, vol. 3, pp. 177–189, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. P. C. Heinrich, I. Behrmann, G. Muller-Newen, F. Schaper, and L. Graeve, “Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway,” The Biochemical Journal, vol. 334, no. 2, pp. 297–314, 1998. View at Publisher · View at Google Scholar
  47. M. Murakami, M. Hibi, N. Nakagawa et al., “IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase,” Science, vol. 260, no. 5115, pp. 1808–1810, 1993. View at Publisher · View at Google Scholar
  48. T. Taga and T. Kishimoto, “Gp130 and the interleukin-6 family of cytokines,” Annual Review of Immunology, vol. 15, pp. 797–819, 1997. View at Google Scholar
  49. C. A. Hunter and S. A. Jones, “IL-6 as a keystone cytokine in health and disease,” Nature Immunology, vol. 16, no. 5, pp. 448–457, 2015. View at Publisher · View at Google Scholar · View at Scopus
  50. M. J. Boulanger, A. J. Bankovich, T. Kortemme, D. Baker, and K. C. Garcia, “Convergent mechanisms for recognition of divergent cytokines by the shared signaling receptor gp130,” Molecular Cell, vol. 12, no. 3, pp. 577–589, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. L. Belec, F. J. Authier, A. S. Mohamed, M. Soubrier, and R. K. Gherardi, “Antibodies to human herpesvirus 8 in POEMS (polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes) syndrome with multicentric Castleman’s disease,” Clinical Infectious Diseases, vol. 28, no. 3, pp. 678-679, 1999. View at Publisher · View at Google Scholar
  52. T. Papo, M. Soubrier, A. G. Marcelin et al., “Human herpesvirus 8 infection, Castleman’s disease and POEMS syndrome,” British Journal of Haematology, vol. 104, no. 4, pp. 932-933, 1999. View at Publisher · View at Google Scholar
  53. L. Belec, A. S. Mohamed, F. J. Authier et al., “Human herpesvirus 8 infection in patients with POEMS syndrome-associated multicentric Castleman’s disease,” Blood, vol. 93, no. 11, pp. 3643–3653, 1999. View at Google Scholar
  54. P. S. Moore, C. Boshoff, R. A. Weiss, and Y. Chang, “Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV,” Science, vol. 274, no. 5293, pp. 1739–1744, 1996. View at Publisher · View at Google Scholar · View at Scopus
  55. D. A. Papanicolaou and A. N. Vgontzas, “Interleukin-6: the endocrine cytokine,” The Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 3, pp. 1331–1333, 2000. View at Publisher · View at Google Scholar
  56. N. A. Sims, B. J. Jenkins, J. M. Quinn, A. Nakamura, M. Glatt, and M. T. Gillespie, “Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways,” The Journal of Clinical Investigation, vol. 113, no. 3, pp. 379–389, 2004. View at Publisher · View at Google Scholar
  57. M. Hashizume and M. Mihara, “High molecular weight hyaluronic acid inhibits IL-6-induced MMP production from human chondrocytes by up-regulating the ERK inhibitor, MKP-1,” Biochemical and Biophysical Research Communications, vol. 403, no. 2, pp. 184–189, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. P. Silacci, J. M. Dayer, A. Desgeorges, R. Peter, C. Manueddu, and P. A. Guerne, “Interleukin (IL)-6 and its soluble receptor induce TIMP-1 expression in synoviocytes and chondrocytes, and block IL-1-induced collagenolytic activity,” The Journal of Biological Chemistry, vol. 273, no. 22, pp. 13625–13629, 1998. View at Publisher · View at Google Scholar · View at Scopus
  59. T. Tamura, N. Udagawa, N. Takahashi et al., “Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 24, pp. 11924–11928, 1993. View at Google Scholar
  60. N. Franchimont, D. Durant, and E. Canalis, “Interleukin-6 and its soluble receptor regulate the expression of insulin-like growth factor binding protein-5 in osteoblast cultures,” Endocrinology, vol. 138, no. 8, pp. 3380–3386, 1997. View at Publisher · View at Google Scholar
  61. N. A. Sims, “gp130 signaling in bone cell biology: multiple roles revealed by analysis of genetically altered mice,” Molecular and Cellular Endocrinology, vol. 310, no. 1-2, pp. 30–39, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. G. D. Roodman, “Interleukin-6: an osteotropic factor?” Journal of Bone and Mineral Research, vol. 7, no. 5, pp. 475–478, 1992. View at Publisher · View at Google Scholar · View at Scopus
  63. K. Insogna, M. Mitnick, J. Pascarella, I. Nakchbandi, A. Grey, and U. Masiukiewicz, “Role of the interleukin-6/interleukin-6 soluble receptor cytokine system in mediating increased skeletal sensitivity to parathyroid hormone in perimenopausal women,” Journal of Bone and Mineral Research, vol. 17, Supplement 2, pp. N108–N116, 2002. View at Google Scholar
  64. A. Grey, M. A. Mitnick, S. Shapses, A. Ellison, C. Gundberg, and K. Insogna, “Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption—a clinical research center study,” The Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 10, pp. 3450–3454, 1996. View at Publisher · View at Google Scholar
  65. I. A. Nakchbandi, M. A. Mitnick, R. Lang, C. Gundberg, B. Kinder, and K. Insogna, “Circulating levels of interleukin-6 soluble receptor predict rates of bone loss in patients with primary hyperparathyroidism,” The Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 11, pp. 4946–4951, 2002. View at Publisher · View at Google Scholar · View at Scopus
  66. D. Dilli and U. Dilmen, “The role of interleukin-6 and C-reactive protein in non-thyroidal illness in premature infants followed in neonatal intensive care unit,” Journal of Clinical Research in Pediatric Endocrinology, vol. 4, no. 2, pp. 66–71, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. P. H. Davies, E. G. Black, M. C. Sheppard, and J. A. Franklyn, “Relation between serum interleukin-6 and thyroid hormone concentrations in 270 hospital in-patients with non-thyroidal illness,” Clinical Endocrinology, vol. 44, no. 2, pp. 199–205, 1996. View at Publisher · View at Google Scholar
  68. H. Abozenah, S. Shoeb, A. Sabry, and H. Ismail, “Relation between thyroid hormone concentration and serum levels of interleukin-6 and interleukin-10 in patients with nonthyroidal illness including chronic kidney disease,” Iranian Journal of Kidney Diseases, vol. 2, no. 1, pp. 16–23, 2008. View at Google Scholar
  69. S. M. Wajner, I. M. Goemann, A. L. Bueno, P. R. Larsen, and A. L. Maia, “IL-6 promotes nonthyroidal illness syndrome by blocking thyroxine activation while promoting thyroid hormone inactivation in human cells,” The Journal of Clinical Investigation, vol. 121, no. 5, pp. 1834–1845, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. K. Nakajima, K. Yamazaki, E. Yamada et al., “Amiodarone stimulates interleukin-6 production in cultured human thyrocytes, exerting cytotoxic effects on thyroid follicles in suspension culture,” Thyroid, vol. 11, no. 2, pp. 101–109, 2001. View at Publisher · View at Google Scholar
  71. A. Waage, G. Slupphaug, and R. Shalaby, “Glucocorticoids inhibit the production of IL6 from monocytes, endothelial cells and fibroblasts,” European Journal of Immunology, vol. 20, no. 11, pp. 2439–2443, 1990. View at Publisher · View at Google Scholar · View at Scopus
  72. A. Tobler, R. Meier, M. Seitz, B. Dewald, M. Baggiolini, and M. F. Fey, “Glucocorticoids downregulate gene expression of GM-CSF, NAP-1/IL-8, and IL-6, but not of M-CSF in human fibroblasts,” Blood, vol. 79, no. 1, pp. 45–51, 1992. View at Google Scholar
  73. J. Veldhuis, R. Yang, F. Roelfsema, and P. Takahashi, “Proinflammatory cytokine infusion attenuates LH’s feedforward on testosterone secretion: modulation by age,” The Journal of Clinical Endocrinology and Metabolism, vol. 101, no. 2, pp. 539–549, 2016. View at Publisher · View at Google Scholar · View at Scopus
  74. S. Ulisse, A. Fabbri, J. C. Tinajero, and M. L. Dufau, “A novel mechanism of action of corticotropin releasing factor in rat Leydig cells,” The Journal of Biological Chemistry, vol. 265, no. 4, pp. 1964–1971, 1990. View at Google Scholar
  75. J. D. Veldhuis, M. J. Wilkowski, A. D. Zwart et al., “Evidence for attenuation of hypothalamic gonadotropin-releasing hormone (GnRH) impulse strength with preservation of GnRH pulse frequency in men with chronic renal failure,” The Journal of Clinical Endocrinology and Metabolism, vol. 76, no. 3, pp. 648–654, 1993. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Maggio, S. Basaria, A. Ble et al., “Correlation between testosterone and the inflammatory marker soluble interleukin-6 receptor in older men,” The Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 1, pp. 345–347, 2006. View at Publisher · View at Google Scholar · View at Scopus
  77. P. Igaz, R. Salvi, J. P. Rey, M. Glauser, F. P. Pralong, and R. C. Gaillard, “Effects of cytokines on gonadotropin-releasing hormone (GnRH) gene expression in primary hypothalamic neurons and in GnRH neurons immortalized conditionally,” Endocrinology, vol. 147, no. 2, pp. 1037–1043, 2006. View at Publisher · View at Google Scholar · View at Scopus
  78. K. Ashawesh and T. M. Fiad, “Spontaneous recovery of adrenal insufficiency in POEMS syndrome,” Medscape Journal of Medicine, vol. 11, no. 1, p. 21, 2009. View at Google Scholar
  79. J. Rosmaninho-Salgado, I. M. Araujo, A. R. Alvaro et al., “Regulation of catecholamine release and tyrosine hydroxylase in human adrenal chromaffin cells by interleukin-1beta: role of neuropeptide Y and nitric oxide,” Journal of Neurochemistry, vol. 109, no. 3, pp. 911–922, 2009. View at Publisher · View at Google Scholar · View at Scopus
  80. B. Samal, D. Ait-Ali, S. Bunn, T. Mustafa, and L. E. Eiden, “Discrete signal transduction pathway utilization by a neuropeptide (PACAP) and a cytokine (TNF-alpha) first messenger in chromaffin cells, inferred from coupled transcriptome-promoter analysis of regulated gene cohorts,” Peptides, vol. 45, pp. 48–60, 2013. View at Publisher · View at Google Scholar · View at Scopus
  81. D. Ait-Ali, V. Turquier, Y. Tanguy et al., “Tumor necrosis factor (TNF)-alpha persistently activates nuclear factor-kappaB signaling through the type 2 TNF receptor in chromaffin cells: implications for long-term regulation of neuropeptide gene expression in inflammation,” Endocrinology, vol. 149, no. 6, pp. 2840–2852, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. R. L. Eskay and L. E. Eiden, “Interleukin-1 alpha and tumor necrosis factor-alpha differentially regulate enkephalin, vasoactive intestinal polypeptide, neurotensin, and substance P biosynthesis in chromaffin cells,” Endocrinology, vol. 130, no. 4, pp. 2252–2258, 1992. View at Publisher · View at Google Scholar · View at Scopus
  83. G. Path, S. R. Bornstein, M. Ehrhart-Bornstein, and W. A. Scherbaum, “Interleukin-6 and the interleukin-6 receptor in the human adrenal gland: expression and effects on steroidogenesis,” The Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 7, pp. 2343–2349, 1997. View at Publisher · View at Google Scholar
  84. R. A. Gadient, A. Lachmund, K. Unsicker, and U. Otten, “Expression of interleukin-6 (IL-6) and IL-6 receptor mRNAs in rat adrenal medulla,” Neuroscience Letters, vol. 194, no. 1-2, pp. 17–20, 1995. View at Publisher · View at Google Scholar · View at Scopus
  85. D. E. Jenkins, D. Sreenivasan, F. Carman, S. Babru, L. E. Eiden, and S. J. Bunn, “Interleukin-6 mediated signaling in adrenal medullary chromaffin cells,” Journal of Neurochemistry, vol. 22, 2016. View at Google Scholar
  86. S. Nusrin, S. K. Tong, G. Chaturvedi, R. S. Wu, J. P. Giesy, and R. Y. Kong, “Regulation of CYP11B1 and CYP11B2 steroidogenic genes by hypoxia-inducible miR-10b in H295R cells,” Marine Pollution Bulletin, vol. 85, no. 2, pp. 344–351, 2014. View at Publisher · View at Google Scholar · View at Scopus
  87. J. V. Seale, S. A. Wood, H. C. Atkinson, M. S. Harbuz, and S. L. Lightman, “Gonadal steroid replacement reverses gonadectomy-induced changes in the corticosterone pulse profile and stress-induced hypothalamic-pituitary-adrenal axis activity of male and female rats,” Journal of Neuroendocrinology, vol. 16, no. 12, pp. 989–998, 2004. View at Publisher · View at Google Scholar · View at Scopus
  88. A. D. Papadopoulos and S. L. Wardlaw, “Testosterone suppresses the response of the hypothalamic-pituitary-adrenal axis to interleukin-6,” Neuroimmunomodulation, vol. 8, no. 1, pp. 39–44, 2000. View at Publisher · View at Google Scholar
  89. L. Xia-Zhang, E. Xiao, and M. Ferin, “A 5-day estradiol therapy, in amounts reproducing concentrations of the early-mid follicular phase, prevents the activation of the hypothalamo-pituitary-adrenal axis by interleukin-1 alpha in the ovariectomized rhesus monkey,” Journal of Neuroendocrinology, vol. 7, no. 5, pp. 387–392, 1995. View at Publisher · View at Google Scholar · View at Scopus
  90. J. J. Puder, P. U. Freda, R. S. Goland, and S. L. Wardlaw, “Estrogen modulates the hypothalamic-pituitary-adrenal and inflammatory cytokine responses to endotoxin in women,” The Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 6, pp. 2403–2408, 2001. View at Publisher · View at Google Scholar
  91. K. Gado, E. Rimanoczi, A. Hasitz et al., “Elevated levels of serum prolactin in patients with advanced multiple myeloma,” Neuroimmunomodulation, vol. 9, no. 4, pp. 231–236, 2001. View at Publisher · View at Google Scholar
  92. K. Gado, G. Nagy, A. Hasitz, B. E. Toth, E. Rimanoczi, and G. Domjan, “Evidence of prolactin immunoreactivity in the bone marrow of untreated multiple myeloma patients,” Neuroimmunomodulation, vol. 9, no. 2, pp. 95–102, 2001. View at Publisher · View at Google Scholar
  93. J. Westin, R. Eyrich, E. Falsen et al., “Gamma heavy chain disease. Reports of three patients,” Acta Medica Scandinavica, vol. 192, no. 4, pp. 281–292, 1972. View at Google Scholar
  94. X. Provatopoulou, D. Georgiadou, T. N. Sergentanis et al., “Interleukins as markers of inflammation in malignant and benign thyroid disease,” Inflammation Research, vol. 63, no. 8, pp. 667–674, 2014. View at Publisher · View at Google Scholar · View at Scopus
  95. J. M. Stouthard, T. van der Poll, E. Endert et al., “Effects of acute and chronic interleukin-6 administration on thyroid hormone metabolism in humans,” The Journal of Clinical Endocrinology and Metabolism, vol. 79, no. 5, pp. 1342–1346, 1994. View at Publisher · View at Google Scholar · View at Scopus
  96. A. R. Hermus, C. G. Sweep, P. N. Demacker, M. J. van der Meer, P. W. Kloppenborg, and J. W. van der Meer, “Continuous infusion of interleukin-1 beta in rats induces a profound fall in plasma levels of cholesterol and triglycerides,” Arteriosclerosis and Thrombosis, vol. 12, no. 9, pp. 1036–1043, 1992. View at Google Scholar
  97. T. van der Poll, K. J. Van Zee, E. Endert et al., “Interleukin-1 receptor blockade does not affect endotoxin-induced changes in plasma thyroid hormone and thyrotropin concentrations in man,” The Journal of Clinical Endocrinology and Metabolism, vol. 80, no. 4, pp. 1341–1346, 1995. View at Publisher · View at Google Scholar · View at Scopus
  98. A. P. Herman, A. Krawczynska, J. Bochenek, E. Dobek, A. Herman, and D. Tomaszewska-Zaremba, “LPS-induced inflammation potentiates the IL-1beta-mediated reduction of LH secretion from the anterior pituitary explants,” Clinical & Developmental Immunology, vol. 2013, Article ID 926937, 2013. View at Publisher · View at Google Scholar · View at Scopus
  99. P. Santana, L. Llanes, I. Hernandez et al., “Ceramide mediates tumor necrosis factor effects on P450-aromatase activity in cultured granulosa cells,” Endocrinology, vol. 136, no. 5, pp. 2345–2348, 1995. View at Publisher · View at Google Scholar · View at Scopus
  100. A. V. Turnbull and C. Rivier, “Inhibition of gonadotropin-induced testosterone secretion by the intracerebroventricular injection of interleukin-1 Beta in the male rat,” Endocrinology, vol. 138, no. 3, pp. 1008–1013, 1997. View at Publisher · View at Google Scholar
  101. K. E. Bethin, S. K. Vogt, and L. J. Muglia, “Interleukin-6 is an essential, corticotropin-releasing hormone-independent stimulator of the adrenal axis during immune system activation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 16, pp. 9317–9322, 2000. View at Google Scholar
  102. N. Rohleder, M. Aringer, and M. Boentert, “Role of interleukin-6 in stress, sleep, and fatigue,” Annals of the New York Academy of Sciences, vol. 1261, pp. 88–96, 2012. View at Google Scholar
  103. L. Bartalena, S. Brogioni, L. Grasso et al., “Interleukin-6: a marker of thyroid-destructive processes?” The Journal of Clinical Endocrinology and Metabolism, vol. 79, no. 5, pp. 1424–1427, 1994. View at Publisher · View at Google Scholar · View at Scopus
  104. R. von Kanel, B. M. Kudielka, D. Preckel, D. Hanebuth, and J. E. Fischer, “Delayed response and lack of habituation in plasma interleukin-6 to acute mental stress in men,” Brain, Behavior, and Immunity, vol. 20, no. 1, pp. 40–48, 2006. View at Publisher · View at Google Scholar · View at Scopus
  105. G. Mastorakos, G. P. Chrousos, and J. S. Weber, “Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans,” The Journal of Clinical Endocrinology and Metabolism, vol. 77, no. 6, pp. 1690–1694, 1993. View at Publisher · View at Google Scholar · View at Scopus
  106. M. P. Pereda, P. Lohrer, D. Kovalovsky et al., “Interleukin-6 is inhibited by glucocorticoids and stimulates ACTH secretion and POMC expression in human corticotroph pituitary adenomas,” Experimental and Clinical Endocrinology & Diabetes, vol. 108, no. 3, pp. 202–207, 2000. View at Publisher · View at Google Scholar · View at Scopus
  107. E. Arzt, “gp130 cytokine signaling in the pituitary gland: a paradigm for cytokine-neuro-endocrine pathways,” The Journal of Clinical Investigation, vol. 108, no. 12, pp. 1729–1733, 2001. View at Publisher · View at Google Scholar
  108. M. Sapochnik, L. E. Nieto, M. Fuertes, and E. Arzt, “Molecular mechanisms underlying pituitary pathogenesis,” Biochemical Genetics, vol. 54, no. 2, pp. 107–119, 2016. View at Publisher · View at Google Scholar · View at Scopus
  109. J. Gloddek, U. Pagotto, M. Paez Pereda, E. Arzt, G. K. Stalla, and U. Renner, “Pituitary adenylate cyclase-activating polypeptide, interleukin-6 and glucocorticoids regulate the release of vascular endothelial growth factor in pituitary folliculostellate cells,” The Journal of Endocrinology, vol. 160, no. 3, pp. 483–490, 1999. View at Publisher · View at Google Scholar
  110. U. Renner, J. Gloddek, M. P. Pereda, E. Arzt, and G. K. Stalla, “Regulation and role of intrapituitary IL-6 production by folliculostellate cells,” Domestic Animal Endocrinology, vol. 15, no. 5, pp. 353–362, 1998. View at Publisher · View at Google Scholar · View at Scopus
  111. K. Yamazaki, E. Yamada, Y. Kanaji et al., “Interleukin-6 (IL-6) inhibits thyroid function in the presence of soluble IL-6 receptor in cultured human thyroid follicles,” Endocrinology, vol. 137, no. 11, pp. 4857–4863, 1996. View at Publisher · View at Google Scholar
  112. A. Salmassi, S. Lu, J. Hedderich, C. Oettinghaus, W. Jonat, and L. Mettler, “Interaction of interleukin-6 on human granulosa cell steroid secretion,” The Journal of Endocrinology, vol. 170, no. 2, pp. 471–478, 2001. View at Publisher · View at Google Scholar · View at Scopus
  113. K. Tamura, T. Kawaguchi, and H. Kogo, “Interleukin-6 inhibits the expression of luteinizing hormone receptor mRNA during the maturation of cultured rat granulosa cells,” The Journal of Endocrinology, vol. 170, no. 1, pp. 121–127, 2001. View at Google Scholar
  114. H. Hakovirta, V. Syed, B. Jegou, and M. Parvinen, “Function of interleukin-6 as an inhibitor of meiotic DNA synthesis in the rat seminiferous epithelium,” Molecular and Cellular Endocrinology, vol. 108, no. 1-2, pp. 193–198, 1995. View at Publisher · View at Google Scholar · View at Scopus
  115. C. V. Perez, C. M. Sobarzo, P. V. Jacobo et al., “Loss of occludin expression and impairment of blood-testis barrier permeability in rats with autoimmune orchitis: effect of interleukin 6 on Sertoli cell tight junctions,” Biology of Reproduction, vol. 87, no. 5, p. 122, 2012. View at Publisher · View at Google Scholar
  116. H. Zhang, Y. Yin, G. Wang, Z. Liu, L. Liu, and F. Sun, “Interleukin-6 disrupts blood-testis barrier through inhibiting protein degradation or activating phosphorylated ERK in Sertoli cells,” Scientific Reports, vol. 4, article 4260, 2014. View at Publisher · View at Google Scholar · View at Scopus
  117. V. Morales, P. Santana, R. Diaz et al., “Intratesticular delivery of tumor necrosis factor-alpha and ceramide directly abrogates steroidogenic acute regulatory protein expression and Leydig cell steroidogenesis in adult rats,” Endocrinology, vol. 144, no. 11, pp. 4763–4772, 2003. View at Publisher · View at Google Scholar · View at Scopus
  118. T. Tokashiki, T. Hashiguchi, K. Arimura, N. Eiraku, I. Maruyama, and M. Osame, “Predictive value of serial platelet count and VEGF determination for the management of DIC in the Crow-Fukase (POEMS) syndrome,” Internal Medicine, vol. 42, no. 12, pp. 1240–1243, 2003. View at Publisher · View at Google Scholar